News stories about Transcat (NASDAQ:TRNS) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Transcat earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news coverage about the scientific and technical instruments company an impact score of 46.091583529171 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Separately, Dougherty & Co assumed coverage on shares of Transcat in a research report on Wednesday. They set a “buy” rating and a $20.00 price objective on the stock.

Shares of Transcat (NASDAQ:TRNS) traded up 1.96% during mid-day trading on Friday, reaching $13.00. 2,303 shares of the company traded hands. Transcat has a 52 week low of $10.00 and a 52 week high of $14.05. The firm has a 50 day moving average of $12.86 and a 200-day moving average of $12.26. The stock has a market capitalization of $92.68 million, a PE ratio of 20.63 and a beta of 0.34.

Transcat (NASDAQ:TRNS) last released its quarterly earnings results on Tuesday, July 25th. The scientific and technical instruments company reported $0.12 earnings per share (EPS) for the quarter. The firm had revenue of $36.28 million for the quarter. Transcat had a return on equity of 10.37% and a net margin of 3.03%. On average, equities research analysts expect that Transcat will post $0.64 EPS for the current fiscal year.

In other Transcat news, Director Carl E. Sassano sold 7,500 shares of Transcat stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $13.02, for a total value of $97,650.00. Following the transaction, the director now directly owns 79,075 shares in the company, valued at approximately $1,029,556.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul D. Moore sold 4,000 shares of Transcat stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $13.00, for a total value of $52,000.00. Following the completion of the transaction, the director now owns 57,698 shares in the company, valued at $750,074. The disclosure for this sale can be found here. Insiders have purchased a total of 2,081 shares of company stock worth $24,924 in the last 90 days. 8.80% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Transcat (TRNS) Stock Price” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/26/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-transcat-trns-stock-price.html.

Transcat Company Profile

Transcat, Inc is a provider of calibration and laboratory instrument services and a distributor of professional grade test, measurement and control instrumentation. The Company conducts its business through two segments: service (Service) and distribution (Distribution). Through the Service segment, the Company offers calibration, repair, inspection, analytical qualifications, preventative maintenance and other related services, a majority of which are processed through its asset management system, CalTrak (CalTrak).

Insider Buying and Selling by Quarter for Transcat (NASDAQ:TRNS)

Receive News & Stock Ratings for Transcat Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat Inc. and related stocks with our FREE daily email newsletter.